Effects of chronic methamphetamine on SCH23390-or haloperidol-induced catalepsy, and effects of coadministration of SCH23390 or haloperidol in mice

Pharmacology Biochemistry and Behavior

Volumn 53, Issue 2, 1996, Pages 437-440

  Mizuki, Yasushi ^a   Ushijima, Itsuko ^a   Yamada, Michio ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Catalepsy; Chronic methamphetamine; Haloperidol; Mice; SCH23390

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG TOLERANCE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; SUPERSENSITIVITY;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; CATALEPSY; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; HALOPERIDOL; MALE; METHAMPHETAMINE; MICE; MICE, INBRED STRAINS; RATS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

ANIMALIA;

EID: 0030041636     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-3057(95)02014-4     Document Type: Article

References (23)

1. 2 dopamine receptor agonists. Eur. J. Pharmacol, 147:441-451; 1988.
2. Carvey, P. M.; Klawans, H. L. Effect of chronic lisuride treatment on stereotypical and myoclonic jumping behavior in guinea pigs. In: Carne, D. B., et al., eds. Lisuride and other dopamine agonists. New York; Raven Press; 1983:79.
3. 1 antagonist SCH23390 in comparison with neuroleptics. Life Sci. 34:1529-1540; 1984.
4. Ellinwood, E. H.; Sudilovski, A.; Nelson, L. J. Evolving behavior in the clinical and experimental amphetamine (model) psychosis. Am. J. Psychiatry 130:1088-1093; 1973.
5. Gerald, M. C.; Riffee, W. H. Acute and chronic effects of d- and I-amphetamine on seizure susceptibility in mice. Eur. J. Pharmacol. 21:323-330; 1973.
6. Globus, M.; Bannet, J.; Lerer, B.; Belmaker, R. H. The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy. Psychopharmacology (Berlin) 78:81-84; 1982.
7. 2 dopamine antagonists with methamphetamine prevent methamphetamine-induced behavioral sensitization and neuro-chemical change, studied by in vivo intracerebral dialysis. Brain Res. 546:40-46; 1991.
8. Janssen, P. A. J.; Niemegeers, S. J. E.; Schellekens, K. H. L. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? 1. "Neuroleptic activity spectra" for rats. Arzneimittelforsch Drug Res. 15:104-117; 1965.
9. Kashihara, K.; Fujiwara, T.; Sato, M. Continuous suppression of methamphetamine-induced supersensitivity by chronic haloperidol administration. Psychiatr. Neurol. Jpn. 86:928-932; 1984 (in Japanese).
10. Klawans, H. L.; Margolin, D. I. Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Arch. Gen. Psychiatry 32:725-732; 1975.
11. Magour, S.; Coper, H.; Fahndrich, C. H. The effects of chronic treatment with d-amphetamine on food intake, body weight, locomotor activity and subcellular distribution of the drug in rat brain. Psychopharmacologia 34:45-54; 1974.
12. 1 antagonist. Life Sci. 36:1857-1864; 1985.
13. Muller, P.; Seeman, P. Presynaptic subsensitivity as a possible basis for sensitization by long-term dopamine mimetics. Eur. J. Pharmacol. 55:149-157; 1979.
14. 2 receptors. Neuropharmacology 25:331-334; 1986.
15. Peroutka, S. J.; Snyder, R. T. Relationship of neuroleptic drug effects at brain dopamine serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am, J. Psychiatry 137:1518-1522; 1980.
16. Post, R. M.; Kopanda, R. T.; Black, K. E. Progressive effects of cocaine on behaviour and central amine metabolism in rhesus monkeys: Relationship to kindling and psychosis. Biol. Psychiatry 11:403-419; 1976.
17. Robinson, T. E.; Becker, J. B. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 11:157-198; 1986.
18. Segal, D. S.; Janowsky, D. S. Psychostimulant-induced behavioral effects: Possible models of shizophrenia. In: Lipton, M. A.; Di Mascio, A.; Killam, K. F., eds. Psychopharmacology: A generation of progress. New York: Raven; 1978:1113-1123.
19. Segal, D. S.; Mandell, A. J. Long-term administration of d-amphetamine: Progressive augmentation of motor activity and stereotypy. Pharmacol. Biochem. Behav. 2:249-255; 1974.
20. Stewart, J.; Vezina, P. Microinjection of SCH23390 into the ventral tegmental area and substantia nigra pars reticulata attenuate the development of sensitization to the locomotor activating effects of systemic amphetamine. Brain Res. 495:401-406; 1989.
21. 1 dopamine receptors in the lateral part of the substantia nigra pars reticulata after subchronic methamphetamine administration. Brain Res. 540:159-163; 1991.
22. 2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Psychopharmacology (Berlin) 98:89-92; 1989.
23. Ushijima, I.; Mizuki, Y.; Yamada, M. Development of tolerance and reverse tolerance to haloperidol- and SCH23390-induced cataleptic effects during withdrawal periods after long-term treatment. Pharmacol. Biochem. Behav. 50:259-264; 1995.